Source comparison
Direct Head-to-Head Comparisons: CJC-1295 No DAC vs Modified GRF(1-29)
Plasma Half-Life 5–7 days (terminal phase) 30–120 minutes Measured via LC-MS/MS in human plasma post-injection Reduced dosing frequency: 2–3×/week vs daily Peak GH Response 10–14 ng/mL at 30–60 min 6–9 ng/mL at 15–30 min Single 100 mcg SC dose in healthy adult
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- 5–7 days (terminal phase)
- 30–120 minutes
- Measured via LC-MS/MS in human plasma post-injection
- Reduced dosing frequency: 2–3×/week vs daily
- Peak GH Response
- 10–14 ng/mL at 30–60 min
- 6–9 ng/mL at 15–30 min
- Single 100 mcg SC dose in healthy adults
- Higher initial amplitude with CJC-1295 No DAC
- Duration Above Baseline
- 5–6 days (>3 ng/mL)
- 90–120 minutes (>3 ng/mL)
- Serial GH sampling every 20 min for 8 hours, daily thereafter
- Sustained pulsatile secretion vs acute spike
- IGF-1 Elevation (7-day AUC)
- +180 ng·day/mL mean
- +45 ng·day/mL mean
- Serum IGF-1 measured daily × 7 days post-dose
- 4× greater cumulative anabolic signaling
- DPP-4 Resistance
- >95% intact at 4 hours
- 60–70% intact at 4 hours
- In vitro human plasma stability assay
- Greater functional stability in circulation
- Professional Assessment
- Preferred for multi-day pulsatile protocols where reduced injection frequency and sustained GH pulses are prioritized
- Optimal for acute studies requiring tight temporal control of GH peaks and rapid washout between trials